On this page

Chlorhexidine Gluconate Oral Rinse

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Chlorhexidine Gluconate Oral Rinse
Generic name
Chlorhexidine Gluconate Oral Rinse
Dosage form
Solution
Route
Dental
Marketing category
ANDA · ANDA
Labeler
Atlantic Biologicals Corp.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
4
Packages
7
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Chlorhexidine Gluconate 1.2 mg/mL 1667684 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Dental
Presentations
11

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Decreased Cell Wall Integrity [PE] PE All 26 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
075561
Application type
ANDA · Abbreviated New Drug Application
Approval date
November 14, 2000
Sponsor
BAJAJ
Products on application
1
Submissions recorded
6
Products approved under application 075561.
Product Trade name Form Strength Ingredient Status TE Flags
075561-001 CHLORHEXIDINE GLUCONATE SOLUTION CHLORHEXIDINE GLUCONATE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 075561.
Type No. Action Status Date Review
Supplement 16 Manufacturing (CMC) Approved May 24, 2024 Unknown
Supplement 14 Manufacturing (CMC) Approved November 17, 2021 Unknown
Supplement 8 Labeling Approved February 28, 2020 Standard
Supplement 2 Labeling Approved October 25, 2001 —
Supplement 1 Manufacturing (CMC) Approved January 26, 2001 —
Original application 1 Approved November 14, 2000 —

Review documents

  • 0 · Original application · November 14, 2000

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260116). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260116 HUMAN PRESCRIPTION DRUG · 20250210

Indications and Usage

openFDA Drug Labeling

INDICATION Chlorhexidine gluconate oral rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine gluconate oral rinse has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS .

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Chlorhexidine gluconate oral rinse therapy should be initiated directly following a dental prophylaxis. Patients using chlorhexidine gluconate oral rinse should be reevaluated and given a thorough prophylaxis at intervals no longer than six months. Recommended use is twice daily oral rinsing for 30 seconds, morning and evening after toothbrushing. Usual dosage is 15 mL (marked in cap) of undiluted chlorhexidine gluconate oral rinse. Patients should be instructed to not rinse with water, or other mouthwashes, brush teeth, or eat immediately after using chlorhexidine gluconate oral rinse. Chlorhexidine gluconate oral rinse is not intended for ingestion and should be expectorated after rinsing.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Chlorhexidine gluconate oral rinse should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

WARNINGS The effect of chlorhexidine gluconate oral rinse on periodontitis has not been determined. An increase in supragingival calculus was noted in clinical testing in chlorhexidine gluconate oral rinse users compared with control users. It is not known if chlorhexidine gluconate oral rinse use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Anaphylaxis, as well as serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine. SEE CONTRAINDICATIONS .

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The most common side effects associated with chlorhexidine gluconate oral rinses are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; see WARNINGS and PRECAUTIONS . Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with use of chlorhexidine gluconate rinse. The following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1%. Among post marketing reports, the most frequently reported oral mucosal symptoms associated with chlorhexidine gluconate oral rinse are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia. Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using chlorhexidine gluconate oral rinse. There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using chlorhexidine gluconate oral rinse.

Description

openFDA Drug Labeling

DESCRIPTION 0.12% chlorhexidine gluconate (CHG) is an oral rinse containing (1, 1'-hexamethylene bis [5-(p-chlorophenyl) biguanide] di-D-gluconate) in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, sodium saccharin, and FD&C Blue No. 1. Chlorhexidine gluconate product is a near-neutral solution (pH range 5-7). Chlorhexidine gluconate is a salt of chlorhexidine and gluconic acid. Its chemical structure is: Struc

OVERDOSAGE Ingestion of 1 or 2 ounces of chlorhexidine gluconate oral rinse by a small child (~10 kg body weight) might result in gastric distress, including nausea, or signs of alcohol intoxication. Medical attention should be sought if more than 4 ounces of chlorhexidine gluconate oral rinse is ingested by a small child or if signs of alcohol intoxication develop.

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Chlorhexidine gluconate oral rinse is supplied as a blue liquid in 0.5-ounce single dose (15 mL) (NDC 16571-128-78), 4-ounce (118 mL) (NDC 16571-128-12) and 1-pint (473 mL) (NDC 16571-128-48) amber plastic bottles with child-resistant closures, and 15 mL (16571-128-15) unit dose cup. STORE at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP controlled Room Temperature]. Rx Only. Revised: 09/2025 Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816

Adverse event reports

Source: openFDA FAERS
9,457
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CHLORHEXIDINE GLUCONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
17856-2128-1 17856-2128 Atlantic Biologicals Corp. 72 CUP, UNIT-DOSE in 1 CASE (17856-2128-1) / 15 mL in 1 CUP, UNIT-DOSE August 4, 2026
17856-2128-2 17856-2128 Atlantic Biologicals Corp. 72 CUP, UNIT-DOSE in 1 CASE (17856-2128-2) / 5 mL in 1 CUP, UNIT-DOSE September 9, 2026
17856-2128-3 17856-2128 Atlantic Biologicals Corp. 50 CUP, UNIT-DOSE in 1 CASE (17856-2128-3) / 30 mL in 1 CUP, UNIT-DOSE September 9, 2026
73614-203-01 73614-203 Brisk Pharmaceuticals 118 mL in 1 BOTTLE (73614-203-01) February 10, 2025
68071-3630-6 68071-3630 NuCare Pharmaceuticals,Inc. 473 mL in 1 BOTTLE (68071-3630-6) June 17, 2024
16571-128-48 16571-128 Rising Pharma Holdings, Inc. 473 mL in 1 BOTTLE (16571-128-48) July 27, 2023
16571-128-52 16571-128 Rising Pharma Holdings, Inc. 100 CUP, UNIT-DOSE in 1 BOX, UNIT-DOSE (16571-128-52) / 15 mL in 1 CUP, UNIT-DOSE (16571-128-15) April 1, 2024
17856-2128 17856-2128 Atlantic Biologicals Corp. — July 27, 2023
73614-203 73614-203 Brisk Pharmaceuticals — July 27, 2023
68071-3630 68071-3630 NuCare Pharmaceuticals,Inc. — July 27, 2023
16571-128 16571-128 Rising Pharma Holdings, Inc. — July 27, 2023

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.